Analysis of outcomes (see Outcomes for detailed definitions) in matched sets in Study 2. Shown are pairwise comparisons between patients in Cohort Fluvoxamine (burdened with conditions requiring antidepressants/anxyolytics and prescribed fluvoxamine, but free of paroxetine, around the time of COVID-19 diagnoses) and Cohort Paroxetine (suffer the same conditions and prescribed peroxetine, but free of fluvoxamine, around the time of COVID-19 diagnosis) (see Table 1 for detailed cohort definitions). Depicted are weighted proportions (percentages) of patients with outcomes in matched sets and respective relative risks (RR). Priors for Bayes estimates: skeptical is moderately informative normal prior centered at 0.0 for Ln(RR) with standard deviation 0.355 – gives equal (50%) probability to an RR above and an RR below unity with 95% probability for an RR between 0.5 and 2.0; optimistic is a moderately informative normal prior centered at -0.199 for Ln(RR) (i.e., 18% relative risk reduction) with standard deviation 0.40 – suggests a benefit but leaves 30% probability of an RR >1.0; pesimistic is a weakly informative normal prior centered at 0.199 for Ln(RR) (i.e., 22% relative risk increase) with standard deviation 0.77 – suggests harm (of the same extent as benefit suggested by the optimistic prior), but leaves 40% probability of an RR <1.0.